Unlocking the Silent Threat: This Common Gene Variant Could Double Dementia Risk in Men—Here’s What You Need to Know Now!

Unlocking the Silent Threat: This Common Gene Variant Could Double Dementia Risk in Men—Here’s What You Need to Know Now!

The ASPREE trial was a double-blind, randomised, placebo-controlled trial of daily low-aspirin in 19,114 healthy older people in Australia and the USA. Primarily undertaken to evaluate the risks versus benefits of daily low-dose aspirin in this cohort, it created a treasure trove of healthy ageing data that has underpinned a wealth of research studies.

The research was a collaboration between Curtin University, Monash University, The University of Melbourne, The Royal Children’s Hospital, Murdoch Children’s Research Institute and Fiona Stanley Hospital.

Pages: 1 2 3 4 5 6 7

Post Comment

You May Have Missed